Global Demand Outlook for Executive Summary Hormone-Refractory Oncology Drug Market Size and Share CAGR Value The global hormone-refractory oncology drug market size was valued at USD 5.33 billion in 2025 and is expected to reach USD 12.46 billion by 2033, at a CAGR of 11.20% during the forecast period A large-scale Hormone-Refractory Oncology Drug Market report comprises of extensive...

According to a new report from Intel Market Research, the global Brigatinib API market was valued at USD 42.5 million in 2025 and is projected to reach USD 89.7 million by 2034, growing at a robust CAGR of 8.1% during the forecast period (2026–2034). This growth is propelled by the increasing global incidence of non-small cell lung cancer, particularly ALK-positive cases among...

According to a new report from Intel Market Research, the global Cabozantinib Drug market was valued at USD 2.12 billion in 2025 and is projected to reach USD 4.01 billion by 2034, growing at a robust CAGR of 7.5% during the forecast period (2026–2034). This growth is propelled by the escalating global burden of cancer, particularly renal and liver cancers, alongside expanding clinical...

According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...

According to a new report from Intel Market Research, the global Selpercatinib Capsules market was valued at USD 420 million in 2025 and is projected to reach USD 820 million by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is propelled by the increasing prevalence of RET-altered cancers, growing adoption of biomarker-driven therapies, and...